{
    "nct_id": "NCT06300411",
    "official_title": "A Phase 1 Study of SRG-514 Administered Intraoperatively to the Site of Tumor Resection of Patients Undergoing Breast-Conserving Cancer Surgery",
    "inclusion_criteria": "* Aged 18 years or older\n* Body weight >50kg\n* Have a history of histologically confirmed diagnosis of breast carcinoma or ductal carcinoma in situ, except inflammatory breast cancer.\n* Plan to undergo breast-conserving surgical treatment of breast cancer with curative intent. Adjuvant or neoadjuvant chemotherapy is allowed.\n* Have Eastern Cooperative Oncology Group (ECOG) Performance Status <2\n* Have adequate organ and bone marrow function at screening\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Any known contraindication to ketorolac or other non-steroidal anti-inflammatory drugs (NSAIDs)\n* Patients anticipated to require the use of a drain after breast-conserving surgery (BCS)\n* Patients undergoing immediate reconstruction surgery, intraoperative radiation therapy (IORT) or brachytherapy requiring the placement of balloons or catheters during the lumpectomy procedure.",
    "miscellaneous_criteria": ""
}